Januvia licenced for triple therapy

on the 30 July 2009

Januvia (sitagliptin) has had its licence extended to include use in triple therapy alongside metformin and a sulfonylurea or a glitazone in type II diabetes inadequately controlled by dual therapy.

The dosage of metformin and glitazone should be maintained and the Januvia dose administered concomitantly.

If it is used in combination with a sulfonylurea, the dose of sulfonylurea may need to be lowered to reduce the risk of hypoglycaemia. The recommended dose of Januvia is 100mg once daily.

View Januvia drug record

Further information: MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Twitter  

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more